Buds & Duds: Cannabis stocks climb after Canopy Growth reports 3Q revenue surge

Also moving were Redfund Capital Corp and GW Pharmaceuticals PLC

A marijuana plant
GW got a boost as Alzheimer’s Research UK announced a trial for cannabis-based Sativex

Cannabis stocks ended the week in positive territory as the release of third-quarter results from Canopy Growth Corp buoyed the market.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, was up 1.5% to 278.88.


Canopy Growth (NYSE:CGC) (TSE:WEED) rallied 4.8% to US$48.25 in Friday’s New York trading after reporting that third-quarter net revenue almost quadrupled from a year earlier.

For the quarter ended December 31, the world’s largest marijuana company in terms of market cap posted net revenue of C$83 million, compared with C$21.7 million a year earlier.

Net income climbed to C$74.9 million, or C$0.22 per share, from C$11 million, or C$0.01 per share a year earlier. On a diluted basis, the company reported a loss of C$0.38 per share.

Shares of the company rose 2.5% to C$62.78 in Canadian trading.

READ: Redfund Capital taps industry veteran Warren D. Cudney as new strategic adviser

Redfund Capital Corp (CSE:LOAN) climbed 11% to C$0.20 after the cannabis-focused financing firm tapped Wahupta Ventures Inc CEO Warren D. Cudney as a member of its advisory team.

Wahupta, a privately held company based in Vancouver, focuses on hemp and cannibidiol cultivation, production, processing and extraction as well as collaborating with North America’s indigenous communities.

Vancouver-based Redfund added that it has extended financing during the first quarter to three cannabis companies: RxMM Health, Mary’s Wellness Ltd and Winterlife Inc.

GW Pharmaceuticals PLC (NASDAQ:GWPH) rose 0.1% to US$151.50 after Alzheimer’s Research UK said in a press release that it’s committing £300,000 for a Phase 2 trial of the company’s cannabis-based Sativex.

The purpose of the trial is to determine whether it’s feasible for the formulation to treat agitation in people with Alzheimer’s disease with the drug. Sativex is licensed in the UK for the treatment of muscle stiffness and tightness experienced by people with multiple sclerosis. It is not currently licensed in the UK for any other indication including treatment of the symptoms of dementia.

Cambridge, England-based GW says on its website that it doesn’t market Sativex.

In November, the company said a second Phase 3 trial of its cannabis-based Epidiolex treatment for a severe form of childhood epilepsy had produced positive results.


Cannabis stocks bucking the positive trend included Aurora Cannabis Inc (NYSE:ACB) (TSE:ACB), which declined 0.1% to US$7.08 in New York trading and was down 0.7% to C$9.36 in Toronto.

Also falling were Green Growth Brands Inc (OTCMKTS:GGBXF) (CSE:GGB), which was down 0.2% to US$4.28 on the OTC Markets and decreased 0.4% to C$5.68 in Canada.

Contact Dennis Fitzgerald at dennis@proactiveinvestors.com

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


First Mining Gold to acquire East Cedartree claims to bolster its Cameron...

First Mining Gold Corp (TSE:FF) (OTCQX:FFMGF) CEO Dan Wilton tells Proactive the group has added more resource ounces and consolidated its ground at the Cameron Gold project in northwest Ontario, by purchasing the East Cedartree claims from Metalore Resources (CVE:MET). Wilton says the...

7 hours, 15 minutes ago

3 min read